MA33241B1 - Composes pour le traitement de troubles metaboliques - Google Patents

Composes pour le traitement de troubles metaboliques

Info

Publication number
MA33241B1
MA33241B1 MA34245A MA34245A MA33241B1 MA 33241 B1 MA33241 B1 MA 33241B1 MA 34245 A MA34245 A MA 34245A MA 34245 A MA34245 A MA 34245A MA 33241 B1 MA33241 B1 MA 33241B1
Authority
MA
Morocco
Prior art keywords
metabolic disorders
compounds
treatment
diabetes
exhibit
Prior art date
Application number
MA34245A
Other languages
Arabic (ar)
English (en)
Inventor
Oscar Barba
Tom Banksia Dupree
Matthew Colin Thor Fyfe
Revathy Perpetua Jeevaratnam
Karen Lesley Schofield
Thomas Staroske
Alan John William Stewart
Simon Andrew Swain
David Matthew Withall
Peter Timothy Fry
Thomas Martin Krulle
David French Stonehouse
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of MA33241B1 publication Critical patent/MA33241B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés thérapeutiques qui présentent une activité d'agonistes de GPR119 et sont utiles pour traiter des troubles métaboliques, y compris le diabète de type 2.
MA34245A 2009-03-12 2010-03-12 Composes pour le traitement de troubles metaboliques MA33241B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0904285.4A GB0904285D0 (en) 2009-03-12 2009-03-12 Compounds for the treatment of metabolic disorders
PCT/GB2010/050441 WO2010103334A1 (fr) 2009-03-12 2010-03-12 Composés pour le traitement de troubles métaboliques

Publications (1)

Publication Number Publication Date
MA33241B1 true MA33241B1 (fr) 2012-05-02

Family

ID=40600947

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34245A MA33241B1 (fr) 2009-03-12 2010-03-12 Composes pour le traitement de troubles metaboliques

Country Status (18)

Country Link
US (1) US20120059014A1 (fr)
EP (1) EP2406251A1 (fr)
JP (1) JP2012520283A (fr)
KR (1) KR20110133045A (fr)
CN (1) CN102395578A (fr)
AU (1) AU2010222672A1 (fr)
BR (1) BRPI1009783A2 (fr)
CA (1) CA2754791A1 (fr)
CL (1) CL2011002182A1 (fr)
EA (1) EA201190207A1 (fr)
GB (1) GB0904285D0 (fr)
IL (1) IL215050A0 (fr)
MA (1) MA33241B1 (fr)
MX (1) MX2011009493A (fr)
PE (1) PE20120218A1 (fr)
SG (1) SG174363A1 (fr)
WO (1) WO2010103334A1 (fr)
ZA (1) ZA201107449B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007007751A1 (de) * 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
AR077214A1 (es) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
EP2547339A1 (fr) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
GB201006167D0 (en) * 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
WO2012066077A1 (fr) 2010-11-18 2012-05-24 Prosidion Limited Dérivés 1,4 di substitués pyrolidine-3-yl-amine et leur utilisation pour le traitement de troubles métaboliques
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
CA2835835C (fr) 2011-05-13 2019-04-02 Array Biopharma Inc. Composes de pyrrolidinyle-uree et de pyrrolidinyle thiouree en tant qu'inhibiteurs de kinase trka
CA2836487A1 (fr) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Nouveaux composes utilises comme modulateurs de gpr-119
GB2497351A (en) * 2011-12-09 2013-06-12 Prosidion Ltd Compounds useful as GPR119 agonists
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2016131198A1 (fr) * 2015-02-18 2016-08-25 Eli Lilly And Company Composés pyrazole
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
EP1123391A2 (fr) 1998-09-01 2001-08-16 BASF Aktiengesellschaft Methodes permettant d'ameliorer la fonction des recepteurs heterologues couples a la proteine g
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP4958560B2 (ja) 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
NZ556017A (en) 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
EP1838706A1 (fr) 2004-12-24 2007-10-03 Prosidion Limited Agonistes du récepteur couplé aux protéines g
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
JP2008545010A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇタンパク質共役受容体アゴニスト
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
NZ571869A (en) 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
WO2007148185A2 (fr) 2006-06-21 2007-12-27 Pfizer Products Inc. 3-amino-pyrrolidino-4-lactames substitués
JP5330260B2 (ja) 2006-12-06 2013-10-30 スミスクライン ビーチャム コーポレーション 二環式化合物ならびに抗糖尿病薬としての使用
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
US20100048625A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine gpcr agonists
PE20081659A1 (es) * 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009034388A1 (fr) 2007-09-10 2009-03-19 Prosidion Limited Composés pour le traitement de troubles métaboliques
KR101136774B1 (ko) 2007-10-18 2012-04-19 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 금속 피복 폴리이미드 복합체 및 그 복합체의 제조 방법 그리고 전자 회로 기판의 제조 방법
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
CN101621337B (zh) 2008-06-30 2013-08-07 华为技术有限公司 一种时延调节装置与方法
AU2009269772A1 (en) 2008-07-10 2010-01-14 Prosidion Limited Piperidinyl GPCR agonists
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
US20110230507A1 (en) 2008-07-10 2011-09-22 Prosidion Limited Piperidine GPCR Agonists

Also Published As

Publication number Publication date
EP2406251A1 (fr) 2012-01-18
JP2012520283A (ja) 2012-09-06
MX2011009493A (es) 2011-10-11
EA201190207A1 (ru) 2012-04-30
ZA201107449B (en) 2012-06-27
BRPI1009783A2 (pt) 2016-03-08
US20120059014A1 (en) 2012-03-08
GB0904285D0 (en) 2009-04-22
WO2010103334A1 (fr) 2010-09-16
CL2011002182A1 (es) 2012-03-30
SG174363A1 (en) 2011-10-28
IL215050A0 (en) 2011-11-30
KR20110133045A (ko) 2011-12-09
CA2754791A1 (fr) 2010-09-16
PE20120218A1 (es) 2012-03-19
CN102395578A (zh) 2012-03-28
AU2010222672A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
MA33241B1 (fr) Composes pour le traitement de troubles metaboliques
MA33190B1 (fr) Composes pour le traitement de troubles metaboliques
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
TW200612926A (en) Compounds and compositions as ppar modulators
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
SG170813A1 (en) New compounds
EP2111107A4 (fr) Agonistes de récepteur hétérocyclique pour le traitement du diabète et de troubles métaboliques
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
IN2012DN02471A (fr)
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200900831A1 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов
TW200602330A (en) Compounds and compositions as PPAR modulators
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.